Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scioderm Inc.

Treating skin lesions and blistering in rare disease

This article was originally published in Start Up

Executive Summary

Scioderm Inc. thinks it can break the long string of failures in wound healing with an experimental therapy called Zorblisa, which it is developing as a topical treatment for epidermolysis bullosa, a rare connective tissue disease that causes skin to tear easily. The FDA has designated it a breakthrough therapy; if Phase III data look good, Scioderm could bring Zorblisa to market in the US and Europe by the end of 2016.

You may also be interested in...



Skin Is In With Biomedical Investors

Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel